文献速递脑血管病认知障碍与痴呆

波士顿标准v2.0在记忆门诊患者中的诊断准确性:MRI-神经病理验证研究

Diagnostic Accuracy of the Boston Criteria v2.0 in Memory Clinic Patients: An MRI-Neuropathology Validation Study.
PubMed 文献 · Neurology · 2026-08-03

本研究基于ADNI与NACC数据,对80例记忆门诊患者(平均年龄81岁,约80%痴呆)回顾性评估波士顿标准v1.5与v2.0对中重度神经病理CAA的诊断准确性。v1.5 probable CAA敏感度32%、特异度87%、AUC 0.59;v2.0敏感度43%、特异度83%、AUC 0.63,两版本总体性能无显著差异。

要点

  • 在记忆门诊人群中,两版波士顿标准对中重度CAA的诊断准确性均有限。
  • v2.0较v1.5敏感度数值升高但特异度下降,总体准确率无显著改善。
  • 基于MRI的CAA标准在非出血性人群需谨慎解读,建议结合其他生物标志物。

核心结论

  • 在记忆门诊患者中,波士顿标准v1.5与v2.0对神经病理证实的CAA总体诊断性能仅为中等。
  • v2.0较v1.5呈现敏感度数值升高、特异度下降的权衡,但总体准确性无显著增益。

研究设计与样本

  • 回顾性诊断准确性研究,纳入ADNI与NACC中具备所需脑MRI和尸检神经病理数据的80例记忆门诊患者。
  • 患者按波士顿标准v1.5和v2.0分为无、可能或很可能CAA,以中重度神经病理CAA为主要参考标准。

主要发现

  • 以中重度CAA为参考,v1.5 probable CAA敏感度32%(95%CI 15%-50%)、特异度87%(77%-95%)、AUC 0.59(0.49-0.69)。
  • v2.0 corresponding values were 敏感度43%(25%-62%)、特异度83%(72%-92%)、AUC 0.63(0.52-0.74)。
  • 两版本间总体性能指标无显著差异;以任何程度神经病理CAA为标准的二次分析呈相似模式。

关键数值与推荐

  • 主要参考标准为中重度神经病理CAA;任何神经病理CAA用于二次/探索性分析。
  • 诊断性能指标包括敏感度、特异度、预测值、似然比、F1分数、准确率及AUC,并进行版本间正式比较。

临床怎么用

  • 在记忆门诊中解读MRI-based CAA标准时应谨慎并结合临床背景。
  • v2.0可能提高检出但需注意特异度下降,非出血性人群可考虑补充其他生物标志物。

局限性

  • 回顾性设计,样本量80例,仅纳入具备脑MRI和尸检神经病理数据的患者。
  • 研究人群约80%为痴呆和阿尔茨海默病,外推至其他记忆门诊人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Cerebral amyloid angiopathy (CAA) is common in older adults and frequently contributes to cognitive impairment and dementia. Existing in vivo diagnostic criteria for CAA (Boston Criteria) were developed primarily in patients with intracerebral hemorrhage, and their performance in memory clinic populations remains uncertain. The updated Boston Criteria v2.0 incorporate nonhemorrhagic MRI markers intended to improve case detection. We evaluated the diagnostic accuracy of the Boston Criteria v1.5 and v2.0 against neuropathologically confirmed CAA in memory clinic patients. METHODS: We performed a retrospective diagnostic accuracy study of participants from the Alzheimer's Disease Neuroimaging Initiative and National Alzheimer's Coordinating Center, selected based on availability of required brain MRI and autopsy-based neuropathology data. Patients were classified as no, possible, or probable CAA according to the Boston Criteria v1.5 and v2.0. The primary reference standard was moderate-to-severe neuropathologic CAA; analyses using any neuropathologic CAA were secondary/exploratory. Diagnostic performance was assessed using sensitivity, specificity, predictive values, likelihood ratios, F1 scores, accuracy, and area under the (receiver-operating characteristic) curve (AUC), with formal comparisons between criteria versions. RESULTS: Eighty patients were included (mean age: 81 years, interquartile range 74-86 years; 36.2% female, ∼80% with dementia and Alzheimer disease). Using moderate-to-severe CAA as the neuropathologic reference standard, probable CAA by Boston Criteria v1.5 had a sensitivity of 32% (95% CI 15%-50%), specificity 87% (77%-95%), and AUC 0.59 (0.49-0.69). Using the Boston Criteria v2.0, the corresponding values were 43% (25%-62%), 83% (72%-92%), and 0.63 (0.52-0.74), respectively. No overall performance measures were significantly different between the criteria versions. Secondary analyses using any neuropathologic CAA showed similar patterns. DISCUSSION: In memory clinic patients, both Boston Criteria versions showed only modest overall diagnostic performance against neuropathology. Compared with v1.5, Boston Criteria v2.0 showed a numerical shift toward greater sensitivity at the expense of specificity but no clear overall gain in accuracy. These findings support cautious, context-dependent interpretation of MRI-based CAA criteria in memory clinic settings and highlight the need for additional biomarkers to improve in vivo diagnosis in nonhemorrhagic populations. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that, in memory clinic populations, Boston Criteria v2.0 show a trade-off between sensitivity and specificity for probable CAA diagnosis, with only modest overall diagnostic accuracy for identifying moderate-to-severe neuropathologically defined CAA.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Kropp E, Varkanitsa M, Stein TD, et al. Diagnostic Accuracy of the Boston Criteria v2.0 in Memory Clinic Patients: An MRI-Neuropathology Validation Study. Neurology. 2026. PMID: 42546232. doi:10.1212/WNL.0000000000218314

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。